Core Insights - Autolus Therapeutics plc is presenting three abstracts at the upcoming European Hematology Association Congress, focusing on the efficacy of its programmed T cell therapy, obecabtagene autoleucel (obe-cel), for adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) [1] Group 1: Clinical Findings - The oral presentation titled "Can CAR T-cell therapy be a definitive treatment for adult r/r B-ALL without transplant?" indicates that 40% of responders to obe-cel are in ongoing remission without subsequent stem cell therapy, suggesting its potential as a definitive treatment [2] - Another oral presentation discusses the efficacy and safety of obe-cel across different age groups, showing favorable outcomes with low incidence of severe cytokine release syndrome (CRS) and neurotoxicity, indicating a positive benefit-risk profile [3] - A poster presentation highlights the potential of the ALL-Hematotox model to better predict outcomes in patients treated with obe-cel compared to the CAR-Hematotox model, suggesting a need for further analysis [4] Group 2: Company Overview - Autolus Therapeutics plc is an early commercial-stage biopharmaceutical company focused on developing next-generation T cell therapies for cancer and autoimmune diseases, utilizing proprietary T cell programming technologies [5] - The company has an FDA-approved product, AUCATZYL, and a pipeline of candidates for treating hematological malignancies and solid tumors [5][7] Group 3: Clinical Trial Information - The FELIX clinical trial of obe-cel enrolled over 100 adult patients with r/r B-precursor ALL, with primary endpoints focused on overall response rate and secondary endpoints including duration of response and safety [6]

Q1 2025 Financial Results and Business Updates May 8, 2025 For Investor communication only. Not for use in product promotion. Not for further distribution. Autolus.com Developing and Delivering a New Generation of T Cell Therapies Disclaimer These slides contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by te ...

Company reports Q1 2025 AUCATZYL® net product revenue of $9.0 millionU.K. Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional marketing authorization for AUCATZYL® for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL)Encouraging preliminary data reported in Phase 1 CARLYSLE trial in systemic lupus erythematosus (SLE); planned Phase 2 pivotal clinical trial in lupus nephritis (LN) and Phase 1 clinical trial in prog ...

Company outlined potential for value creation driven by obe-cel across multiple B cell driven malignancies and autoimmune diseases, including acute lymphoblastic leukemia (ALL), lupus nephritis (LN) and multiple sclerosis (MS)Preliminary data in initial six patient cohort treated in Phase 1 trial in systemic lupus erythematosus (SLE) support progressing obe-cel into a planned Phase 2 pivotal study in lupus nephritis; first patient expected to be dosed in Phase 2 trial by year-end 2025Company plans to advanc ...

Company outlined potential for value creation driven by obe-cel across multiple B cell driven malignancies and autoimmune diseases, including acute lymphoblastic leukemia (ALL), lupus nephritis (LN) and multiple sclerosis (MS)Preliminary data in initial six patient cohort treated in Phase 1 trial in systemic lupus erythematosus (SLE) support progressing obe-cel into a planned Phase 2 pivotal study in lupus nephritis; first patient expected to be dosed in Phase 2 trial by year-end 2025Company plans to advanc ...

LONDON, April 02, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in the 24th Annual Needham Virtual Healthcare Conference. Autolus Chief Executive Officer Dr. Christian Itin will present in a Fireside Chat on Wednesday, April 9, 2025 at 9:30am EDT / 14:30pm BST. A webcast of the fireside chat will be available ...

Core Insights - Autolus Therapeutics plc will host an R&D investor event on April 23, 2025, to discuss updates on its clinical pipeline and expansion plans [1][2] Group 1: Company Overview - Autolus Therapeutics plc is an early commercial-stage biopharmaceutical company focused on developing next-generation T cell therapies for cancer and autoimmune diseases [4] - The company utilizes proprietary T cell programming technologies to create targeted and effective therapies [4] - Autolus has an FDA-approved product, AUCATZYL, and is developing additional candidates for hematological malignancies, solid tumors, and autoimmune diseases [4] Group 2: Upcoming Event Details - The R&D investor event will take place in New York City at 8:30am EDT / 13:30pm BST [1] - The company will present initial data from the CARLYSLE Phase 1 trial in systemic lupus erythematosus and discuss plans for expansion in autoimmune diseases [2] - A webcast of the presentation will be available on the company's website, with a replay archived for 90 days [3]